ABLYNX ANNOUNCES HALF-YEAR RESULTS FOR 2009

* Reuters is not responsible for the content in this press release.

Thu Aug 27, 2009 12:28pm EDT 

  GHENT, BELGIUM, Aug 27 (MARKET WIRE) -- 

REGULATED INFORMATION

    GHENT, Belgium, 27 August 2009 - Ablynx [Euronext Brussels: ABLX],
announced today its results for the six month period ending 30 June 2009,
which have been prepared in accordance with the IAS 34 'Interim Financial
Reporting' as adopted by the European Union.

    H1 2009 Highlights


-- EUR 101.8 million in cash, cash equivalents and financial assets at
   30 June 2009
-- 93% increase in revenues to EUR 11.9 million (2008: EUR 6.2 million)
-- Reported detailed positive Phase Ib results in patients for its
   anti-thrombotic Nanobody(R) ALX-0081 and progressed to an extended
   Phase 1b study
-- Ablynx's vWF Nanobody(R) programme for the treatment of thrombotic
   thrombocytopenic purpura (TTP) was granted orphan drug
   designation in both Europe and the USA
-- Announced a new preclinical development candidate, ALX-0061, a
   Nanobody(R) binding to IL6R, for the treatment of autoimmune and
   inflammatory diseases
-- Announced important technology developments in pulmonary delivery
   and novel proprietary half-life extension of Nanobodies(R)
-- Received a EUR 3 million milestone from Boehringer Ingelheim as part
   of the strategic alliance for the development and commercialisation of
   Nanobodies(R)
-- Novartis and Wyeth Pharmaceuticals both extended their research
   collaborations with Ablynx for a further 12 months
-- Ablynx strengthened its senior team with the appointment of a new
   Chief Scientific Officer, a Medical Director and a new Business
   Development Director
-- Increased staff to over 220 people by period end
-- Continued preparations for the move to new 7,000 m2 facility in
   mid-2010

    
Complete version of the press release in
English:
http://hugin.info/137912/R/1337716/318883.pdf


For more information, please contact:

For international media enquiries:
College Hill Life Sciences
Sue Charles, Justine Lamond,
Dr. John McIntyre
t:   +44 (0)20 7866 7857
e:  ablynx@collegehill.com

Ablynx:
Dr. Edwin Moses
Chairman and CEO
t:   +32 (0)9 262 00 07
m: +44 (0)7771 954 193 /
     +32 (0)473 39 50 68
e:  edwin.moses@ablynx.com

Eva-Lotta Allan
Chief Business Officer
t:   +32 (0)9 262 00 75
m: +32 (0)475 78 36 21 /
     +44 (0)7990 570 900
e:  eva-lotta.allan@ablynx.com

    


This announcement was originally distributed by Hugin. The issuer is
solely responsible for the content of this announcement.


 Copyright
Copyright Hugin AS 2009. All rights reserved.

    

For more information, please contact:

For international media enquiries:
College Hill Life Sciences
Sue Charles, Justine Lamond,
Dr. John McIntyre
t:   +44 (0)20 7866 7857
e:  Email Contact

Ablynx:
Dr. Edwin Moses
Chairman and CEO
t:   +32 (0)9 262 00 07
m: +44 (0)7771 954 193 /
     +32 (0)473 39 50 68
e:  Email Contact

Eva-Lotta Allan
Chief Business Officer
t:   +32 (0)9 262 00 75
m: +32 (0)475 78 36 21 /
     +44 (0)7990 570 900
e:  Email Contact

Copyright 2009, Market Wire, All rights reserved.

-0-
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.